Acellular human dermal allografts have been shown to be effective for soft-tissue implantation. We compared treatment outcomes of
tympanoplasty using tragal perichondrium and acellular human dermal allograft (MegaDerm®). In a prospective randomised controlled
study, 60 patients scheduled to undergo tympanoplasty were randomly assigned to the autologous tragal perichondrium group (n = 33) or
acellular human dermal allograft group (n = 27). Postoperative hearing gain, graft success rate at 1 and 6 months and operation times were
compared between groups. Graft success rate, defined as the complete closure of tympanic membrane perforation, did not show any significant
intergroup difference (75.8% vs 85.2%, p = 0.519). Air conduction thresholds and air-bone gaps showed significant improvements in
both groups; from 38.7 ± 15.9 dB to 30.2 ± 15.6 dB (p < 0.001) and from 17.8 ± 7.3 dB to 11.5 ± 7.0 (p = 0.001) in the autologous tragal
perichondrium group, and from 30.4 ± 12.2 dB to 24.5 ± 13.0 dB (p = 0.006) and from 14.3 ± 5.1 dB to 7.6 ± 4.6 dB (p < 0.001) in the
acellular human dermal allograft group. The amount of hearing gain (p = 0.31) and closure of air-bone gap (p = 0.863) were not meaningfully
different between groups. The mean operation time was significantly lower in the acellular human dermal allograft group (35.2 min
vs 27.4 min, p = 0.039). In this prospective randomised controlled study, acellular human dermal allograft was shown to be an effective
alternative to tragal perichondrium, with similar graft success rates and postoperative hearing results, but with reduced operation times.


Perforation of the tympanic membrane (TM) is a common disorder encountered by otologists. It is caused by trauma, chronic otitis media, or as a complication of otologic surgeries, and presents with conductive hearing loss. The goals of tympanoplasty are to obtain an intact TM, eradicate pathological tissues in the middle ear and mastoid and reconstruct the sound transmission mechanism.

Since first described by Berthold in 1878, various materials have been used for TM grafting 1. Mostly, tissue located near the operative field is harvested for grafting, and temporalis fascia and tragal perichondrium are the most commonly used grafting materials 2. These materials may be used solely or compositely such as perichondrium-cartilage island graft 3. In addition, various allografts, xenografts and alloplasts have been used in tympanoplasty 4. Among the various materials, human acellular dermal matrix has been used for TM grafting since late 20th century with promising results. However, there has been few prospective randomised trials to provide objective evidence justifying the use of this material. MegaDerm® (L&C BIO, Seongnam-si, Korea) is one such human acellular dermal allograft derived from donated human skin that is supplied by US tissue banks under the guidelines of the American Association of Tissue Banks and US Food and Drug Administration. It consists of an intact basement membrane matrix processed directly from cadaveric skin, and allows for revascularisation by the recipient’s native fibroblasts and endothelial cells 5. Previous human acellular dermal allografts (e.g., AlloDerm, LifeCell Corp., Branchbug, MJ, USA) are offered as an aseptic material; they are processed using methods to prevent, restrict, or minimise contamination with microorganisms. MegaDerm® is a sterile and non-immunogenic acellular dermal allograft. While processing the material, the cellular components of the epidermis and dermis are removed to allow the graft to be tolerated in the host without inciting an immune response 6. While sterility cannot be assured in an aseptic condition, MegaDerm® is produced using electron-beam sterilisation to eliminate viruses, bacteria and spores, achieving a 10-6 sterility level. Thus, theoretically, the use of a sterile allograft may also reduce the risk of infection.

MegaDerm® has been shown to be effective in breast reconstruction 7, and numerous clinical applications including rhinoplasty, penile augmentation, rotator cuff repair and preventing skin retraction after thyroidectomy and parotidectomy are under investigation. The use of MegaDerm® as a TM graft provides several benefits over native tissue. It can eliminate donor site morbidity, provide enough amount for grafting at any time and preserve native tissue for later use. In revision cases, in which the native tissue has already been consumed, it can be a good alternative available in infinite quantity. Moreover, since the procedures for harvesting and preparing graft tissue are unnecessary, operation times can also be reduced.

Herein, we compared a group of similar, consecutive patients undergoing type I tympanoplasty using MegaDerm® and native tissue (tragal perichondrium) in a prospective randomised controlled study. We compared outcomes of successful closure of TM perforation, audiologic outcomes and operation times for the different graft materials.

Materials and methods


Sixty patients who underwent type I tympanoplasty for TM perforation between March 2015 and March 2016 were included in the study. They were between 14 and 79 years of age (mean age = 53.3 years); 17 (28.3%) were men and 43 (71.7%) were women. Patients who underwent other procedures (e.g., ossiculoplasty or mastoidectomy) simultaneously were excluded. None had a history of previous ear surgery, and their ear canal and middle ear were completely dried up without otorrhoea. Preoperative records showed that all of the perforations failed to close spontaneously over a 6-month period. They were randomly assigned to the native-tissue group (tympanoplasty using tragal perichondrium) or the MegaDerm® group (tympanoplasty using MegaDerm®). A third person assigned patients to each group by using a random number table, and informed the surgeon which materials were to be used on the same day of surgery. TM perforation was assessed using a 0°, 3 mm diameter straight telescope (Karl Storz GmbH & Co. KG, Tuttlingen, Germany) and a high-definition liquid crystal display monitor (Olympus, Tokyo, Japan). The perforations were grouped according to Saliba’s subdivision 8 as follows: small, less than 25% and less than 1 quadrant size of the total TM; medium, more than 25% and less than 50%, and more than 1 quadrant and less than 2 quadrant size; large, more than 50% but not total, and more than 2 quadrant size but not total; and total, 100% and 4 quadrant size. Patient information is listed in Table I.

All procedures were in accordance with the Declaration of Helsinki of 1964. The study was approved by the Institutional Review Board of the Severance Hospital in Seoul, Korea (approval number: 4-2014-1072) and informed consent was obtained from all enrolled patients before surgery.

Surgical procedure

All patients underwent type I tympanoplasty via the transcanal approach under local anaesthesia. An ear speculum was inserted into the external auditory canal to visualise the perforation. The margins of the perforation were trimmed by using a sharp pick. Then, the tympanomeatal flap was elevated, and the graft material was placed via an underlay technique. After grafting, the external auditory canal was packed with antibiotic-coated gelfoam and sealed using an aseptic cotton ball and plaster. Patients were prescribed broad-spectrum oral antibiotics for 1 week. All patients were discharged the same day.

In the native-tissue group, the tragal perichondrium was harvested as the graft. An additional skin incision was made over the tragus, and the perichondrium was harvested. Thereafter, the incision site was sutured with 4-0 nylon. In the MegaDerm® group, a 1.5 × 2 cm graft (thickness = 0.3-0.5 mm) was used.

Assessment of treatment outcomes

Packing materials were completely removed at 2 weeks postoperatively, and the TM was assessed at 1 and 6 months using the same device described above. Graft success was defined as closure of the TM perforation.

All patients underwent pure-tone audiography before, and at 1 and 6 months after surgery. Pure-tone air conduction (AC, 250-8,000 Hz) and bone conduction (BC, 250-4,000 Hz) thresholds were measured using clinical audiometers in a double-walled audio booth. The average hearing threshold and air-bone gap (ABG) was defined as the mean value of the measurements taken at frequencies 500 Hz, 1 kHz, 2 kHz, and 3 kHz. Postoperative hearing gain and closure of ABG were calculated by subtracting the mean preoperative AC thresholds from the mean postoperative AC thresholds, and by subtracting the postoperative ABG from the preoperative ABG in both groups, respectively. Any complications that developed during the follow-up period were analysed.

Operation time

Operation time, defined as the interval between the time of ear speculum insertion into the ear canal and time of postoperative dressing application, was analysed.

Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 21.0 (IBM Corp., Armonk, NY, USA). The results of multiple experiments are presented as the mean ±standard deviation. Comparisons between continuous variables in two groups were performed using a Student’s t-test or the paired t-test for evaluating differences between two groups if the normality test was passed. Otherwise, the Mann-Whitney test or Wilcoxon signed rank test were applied. Comparisons between nominal variables in two groups were performed using Fisher’s exact test. A p value of 0.05 was considered as the threshold for significance.


Among 60 patients, 27 (45.0 %) received MegaDerm®. Preoperative hearing level and ABGs for the two groups were not significantly different (p > 0.05, Table I). Age, perforation size and site of graft were not significantly different between the groups (p > 0.05, Table I), but the number of female patients was higher in the MegaDerm® group (p = 0.031, Table I).

Success in closing TM perforations

At 1 month postoperatively, 53 perforations were closed. However, six perforations in the native-tissue group (18.2%) and two in the MegaDerm® group (7.4%) remained. The success rates for the two groups at 1 month were not significantly different (p = 0.276).

Among six perforations in the native-tissue group, two spontaneously closed at 6 months postoperatively. Three perforations remained at 6 months; but since their sizes were small and the patients were free from any ear symptoms; revision surgeries were not necessarily performed (Fig. 1A). One patient with remnant perforation needed revision surgery. It was a small-sized perforation located on the anteroinferior quadrant of the TM preoperatively (Fig. 2A), and a new perforation developed in the posterior margin of the TM after tympanoplasty (Fig. 2B). Four perforations newly developed at 6 months postoperatively. Three of these were followed up without revision surgery for the same reasons as above; however, one perforation needed revision surgery. It was initially a medium-sized perforation (Fig. 2C) and was completely closed at 1 month postoperatively. At 6 months, an otoscopic examination revealed a small-sized perforation with granulation tissue and otorrhoea growing in the middle ear space (Fig. 2D). Consequently, the graft success rate for the native-tissue group at 6 months was 75.8% (25/33), with two revision surgeries and six small pin-point perforations.

In the MegaDerm® group, two perforations were observed at 1 month postoperatively, and one needed revision surgery. One was a large-sized perforation preoperatively (Fig. 2E), and had minimally decreased in size at 1 month postoperatively (Fig. 2F); therefore, revision surgery was performed. The other perforation was observed without additional treatment (Fig. 1B). Two perforations newly developed at 6 months postoperatively, and their sizes were so small that they were not treated. Therefore, the graft success rate for the MegaDerm® group at 6 months was 85.2% (23/27), with one revision surgery and three small pin-point perforations.

Consequently, 25 perforations from the native-tissue group and 23 perforations from the MegaDerm® group were successfully incorporated into the host TM without perforation (Fig. 3). The success rates for the two groups at 6 months were not significantly different (p = 0.519).

We next determined if the graft success rate was dependent on the size and location of the perforation. Among the eight perforations in the native tissue group in which perforations failed to close, four were small-sized, and four were medium-sized. Among the four perforations in the MegaDerm® group, two were small-sized, one was medium-sized and one was large-sized. In the native tissue group, two of the small-sized perforations were located anterosuperior and two were anteroinferior. In the native tissue group, one of the medium-sized perforations was located centrally, one was anterior and two were inferior. Two small-sized perforations of MegaDerm® group were located at anteroinferior quadrant of the drums, and a medium-sized perforation of MegaDerm® group was located at inferior region. Proportion of size and location of the perforations did not significantly differ between groups (Table II).

The size and location of the perforation and graft success rates were analysed. Perforations were initially classified into four groups, anterior small (n = 26), posterior small (n = 1), anterior medium (n = 11) and posterior medium (n = 1); the others, such as central or inferior perforations, were excluded due to the small number of cases. Of these, six anterior small-sized perforations and one anterior medium-sized perforation failed to close. However, no statistically significant differences were found between groups (p = 0.694) in the size of the perforations (p = 0.303) or the location of the perforations (p = 0.503). The overall graft success rate was also not significantly different between the two groups (p = 0.519). There was no difference in the successful closure of TM perforation based on size, location, or graft materials (Table II).

Hearing results

At 1 month postoperatively, the AC threshold improved from 41.6 ± 18.2 dB to 35.2 ± 20.1 dB (p < 0.001), and the BC threshold stabilised from 23.4 ± 17.0 dB to 22.2 ± 17.6 dB (p = 0.057) in the native-tissue group. Similar results were observed in the MegaDerm® group. The AC threshold improved from 36.4 ± 17.1 dB to 31.3 ± 8.6 dB (p < 0.001), and the BC threshold stabilised from 20.9 ± 14.9 dB to 19.7 ± 17.1 dB (p = 0.240). Hearing gain between the two groups was not significantly different (p = 0.455, Fig. 4A, 4B). ABG was significantly reduced in both groups, from 18.1 ± 6.8 dB to 13.1 ± 6.4 dB (p < 0.001) in the native-tissue group and from 15.5 ± 5.3 dB to 11.7 ± 5.7 dB (p = 0.002) in the MegaDerm® group. Therefore, ABG was reduced by 5.1 ± 7.0 dB in the native-tissue group and by 3.8 ± 5.7 dB in the MegaDerm® group, which was not significantly different (p = 0.455, Fig. 5A).

Serial pure-tone audiograms were acquired in 34 patients (17 from each group) at 6 months postoperatively. The other 26 patients referred no discomfort in subjective hearing and refused to undergo hearing tests. The AC threshold improved from 38.7 ± 15.9 dB to 30.2 ± 15.6 dB (p < 0.001) in the native-tissue group, and from 30.4 ± 12.2 dB to 24.5 ± 13.0 dB (p = 0.006) in the MegaDerm® group. The BC threshold stabilised from 20. 9 ± 15.4 dB to 18.8 ± 15.5 dB (p = 0.096) and from 16.0 ± 10.0 dB to 16.8 ± 11.1 dB (p = 0.522) in the native-tissue and MegaDerm® groups, respectively. Hearing gain was not different between the groups (p =0.31, Fig. 4C, 4D). Both groups showed significantly reduced ABGs at 6 months postoperatively: 17.8 ± 7.3 dB to 11.5 ± 7.0 (p = 0.001) in the native-tissue group and 14.3 ± 5.1 dB to 7.6 ± 4.6 dB (p < 0.001) in the MegaDerm® group. The amount of reduction in ABGs was similar between the groups (p = 0.863, Fig. 5B).


Except for the re-perforation or incomplete TM closure described above, few complications were observed. Myringitis was reported in one patient in each group. They were treated with otic solution and oral medication, and the myringitis resolved without re-perforation. However, another patient from the native-tissue group had middle ear infection with re-perforation, requiring revision surgery (Fig. 2B). One patient from the native-tissue group experienced donor-site perichondritis, which resolved without complications after oral medication.

Operation time

The mean operation time was 35.2 ± 15.6 min in the native-tissue group and 27.4 ± 13.2 min in the MegaDerm® group. The operation times were significantly lower in the MegaDerm® group (p = 0.039).


There are several advantages to performing tympanoplasty using a human acellular dermal allograft. First, the operation time can be significantly reduced. In our study, the use of MegaDerm® helped save on average 7.8 min over the use of tragal perichondrium. The longer operation time for autologous tissue grafting was because of the harvesting and handling of the graft material. Since MegaDerm® is prepared in a dried condition, surgeons do not need to wait for the material to dry as preferred, and can easily trim the material into the proper size and shape. MegaDerm® is as thick as 0.3-0.5 mm, which is generally thicker than native tissues, though still pliable, and the thickness and elasticity provide stability while handling the material.

Second, an additional incision for harvesting the graft material is unnecessary when using MegaDerm®, thus reducing donor-site morbidity. In cases in which tympanoplasty is performed via the transcanal approach, an additional incision is mandatory for harvesting the graft material unlike tympanoplasty via the retroauricular approach in which the temporalis fascia can be harvested via the same surgical site. This can reduce the probability of donor-site infection or deformity induced by injury to tragal cartilage. Reported donor-site infection is rare, but cannot be excluded 9.

Third, the limitless supply of MegaDerm® is another advantage. In cases of revision surgery, finding enough suitable fascia or perichondrium is sometimes difficult, especially if the patient has undergone multiple surgeries. Finding autogenous tissues for grafting can be another time-consuming procedure and may increase donor-site morbidity. The authors also use MegaDerm® in canal-wall-down mastoidectomy with tympanoplasty and revision surgery, and the limitless supply of graft material could contribute to stable healing.

MegaDerm® further offers an immunogenic benefit. The safety of acellular dermal matrix allografts has been well demonstrated in both animal 10 11 and clinical studies 12. Moreover, MegaDerm® is a sterile allograft produced by removing the antigenic target of cell-mediated rejection. A previous study comparing the rate of postoperative infection between sterile allograft and aseptic allograft in breast reconstruction showed the superiority of the immunologic aspects of MegaDerm® 13. Although a direct comparison of these two materials in tympanoplasty has not yet been performed or reported, it can be stated that at least there is no harm in utilising MegaDerm® over native tissue or conventional allografts in view of its immunogenic superiority.

In addition to the many advantages described above, MegaDerm® provides comparable functional benefits. Graft success rate varies according to materials and study designs. Success rates reported in retrospective studies were mostly higher than those reported in prospective studies, regardless of the graft material used. In 2008, Gamra et al. reported a success rate of 97.7% for cartilage from 90 tympanoplasties, and a success rate of 96.9% for temporalis fascia from 290 tympanoplasties 14. Solmaz et al. performed 194 tympanoplasties with perichondrium-cartilage island graft, and the success rate was 91.24% 3. A few other retrospective studies have reported similar outcomes. However, there are only two prospective studies reporting success rates for cartilage and temporalis fascia. Yung et al. reported 84.2% and 80.0% success rates and Mauri et al. reported 86.1% and 88.2% success rates for temporalis fascia and cartilage 15 16. The reported success rates are quite comparable to those of MegaDerm® in this study. The success rate for allografts was similar to those for autologous materials. One study that performed tympanoplasty using allografts showed an 88% success rate 17, and another reported a 78% success rate for TM closure 18. With respect to hearing results, a prospective study with a large population of 553 patients reported 12 month follow-up data; both AC and ABG improved from 32.1 dB to 29.7 dB and from 21.2 dB to 19.1 dB at 1 year postoperatively, respectively, 19 and the improvement was comparable to that seen in our study.

Since the first commercial use of allograft in tympanoplasty in 1999, the advantages of this procedure have been widely reported 20. Numerous studies have provided evidence for its safety and efficacy, including animal studies 21 22 and retrospective studies that compared and analysed methods and results 2 17 23. To our knowledge, the present study is the first and only prospective randomised controlled study in human patients demonstrating the advantages of the procedure. Therefore, the present study provides stronger support for the safety and efficacy of using allograft in tympanoplasty.

Nevertheless, our study has some limitations. The function of the Eustachian tube highly affects the outcome of tympanoplasty in both disease recurrence and hearing improvement 24 25. Age, site of graft, perforation size and hearing level were matched in both groups, but the function of the Eustachian tube was neither assessed nor compared. Although there is no available definite method that reflects the function of the Eustachian tube, information on preoperative Eustachian tube function could provide better comparison between groups and with previous reports. Second, a 6 month follow-up period is likely to be sufficient to compare the efficacy of the materials; however, for better comparison, longer-term follow-up with more subjects is needed.


Compared to autologous graft materials, MegaDerm® is an effective alternative as a TM graft material with similar graft success rates and postoperative hearing results, but with reduced operation times.

Figures and tables

Fig. 1..

Fig. 2..

Fig. 3..

Fig. 4..

Fig. 5..

Table I..

Variables Native Tissue Group (n = 33) MegaDerm Group (n = 27) P value
Age (yr) 53.7 ±15.2 52.8 ±13.5 0.808
Sex, n (%) Male Female 13 (39.4%) 20 (60.6%) 4 (14.8%) 23 (85.2%) 0.031
Site of graft, n (%) Right Left 16 (48.5%) 17 (51.5%) 9 (33.3%) 18 (66.7%) 0.244
Perforation Size, n (%) Small Medium Large Total 16 (48.5%) 16 (48.5%) 1 (3.0%) 0 (0) 13 (48.1%) 9 (33.3%) 4 (14.8%) 1 (3.8%) 0.295
Hearing level (dB HL) Air conduction Bone conduction Air-bone gap 41.6 ±18.2 23.4 ±17.0 18.1 ± 6.8 36.4 ±17.1 20.9 ±14.9 15.5 ± 5.3 0.266 0.548 0.106
Demographic and clinical characteristics of the study groups.

Table II..

Variables Native Tissue Group (n = 33) MegaDerm Group (n = 27)
Small • Anterosuperior • Anteroinferior • Posterosuperior • Posterioinferior • Central 16 (48.5%) 4 11 0 0 1 13 (48.1%) 0 11 0 1 1
Medium • Anterior • Posterior • Inferior • Central 16 (48.5%) 7 0 6 3 9 (33.3%) 4 1 4 0
Large 1 (3.0%) 4 (14.8%)
Total 0 (0) 1 (3.8%)
Perforation size and location.